CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 55,263	$ 70,052
Short-term investments	309,500	402,301
Contracts receivable	1,858	1,242
Inventories	2,915	2,484
Other current assets	7,553	7,058
Total current assets	377,089	483,137
Property, plant and equipment, net	98,019	35,703
Licenses, net	10,562	12,288
Patents, net	16,994	15,821
Deposits and other assets	3,121	3,528
Total assets	505,785	550,477
Current liabilities:
Accounts payable	6,653	6,523
Accrued compensation	5,233	6,831
Accrued liabilities	15,071	12,389
Current portion of long-term obligations	4,157	5,645
Current portion of deferred contract revenue	52,428	74,502
Total current liabilities	83,542	105,890
Long-term deferred contract revenue	19,415	50,413
2 5/8 percent convertible subordinated notes	139,239	132,895
Long-term obligations, less current portion	4,724	5,720
Long-term financing liability for leased facility	68,895	10,147
Investment in Regulus Therapeutics Inc.	3,145	870
Total liabilities	318,960	305,935
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 99,723,317 and 99,393,780 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively	100	99
Additional paid-in capital	1,009,330	1,000,181
Accumulated other comprehensive income	(1,153)	949
Accumulated deficit	(821,452)	(756,687)
Total stockholders' equity	186,825	244,542
Total liabilities and stockholders' equity	$ 505,785	$ 550,477